Inhibition of P-glycoprotein-mediated drug transport - A unifying mechanism to explain the interaction between digoxin and quinidine

被引:324
作者
Fromm, MF
Kim, RB
Stein, CM
Wilkinson, GR
Roden, DM
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA
关键词
antiarrhythmia agents; brain; drugs; pharmacology; P-glycoprotein;
D O I
10.1161/01.CIR.99.4.552
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Although quinidine is known to elevate plasma digoxin concentrations, the mechanism underlying this interaction is not fully understood. Digoxin is not extensively metabolized, but it is known to be transported by the drug, efflux pump P-glycoprotein, which is expressed in excretory tissues (kidney, liver, intestine) and at the blood-brain barrier. Accordingly, we tested the hypothesis that inhibition of P-glycoprotein-mediated digoxin transport by quinidine contributes to the digoxin-quinidine interaction. Methods and Results-First, we demonstrated active transcellular transport of both digoxin and quinidine in cultured cell lines that express P-glycoprotein in a polarized fashion. In addition, 5 mu mol/L quinidine inhibited P-glycoprotein-mediated digoxin transport by 57%. Second, the effect of quinidine on digoxin disposition was studied in wild-type and in mdr1a(-/-) mice, in which the gene expressing the major digoxin-transporting P-glycoprotein has been disrupted. Because the in vitro data showed that quinidine itself is a P-glycoprotein substrate, quinidine doses were reduced in mdr1a(-/-) mice to produce plasma concentrations similar to those in wild-type control animals. Quinidine increased plasma digoxin concentrations by 73.0% (P=0.05) in wild-type animals, compared with 19.5% (P=NS) in mdr1a(-/-) mice. Moreover, quinidine increased digoxin brain concentrations by 73.2% (P=0.05) in wild-type animals; by contrast, quinidine did not increase digoxin brain concentrations in mdr1a(-/-) mice but rather decreased them (-30.7%, P<0.01). Conclusions-Quinidine and digoxin are both substrates for P-glycoprotein, and quinidine is a potent inhibitor of digoxin transport in vitro. The in vivo data strongly support the hypothesis that inhibition of P-glycoprotein-mediated digoxin elimination plays an important role in the increase of plasma digoxin concentration occurring with quinidine coadministration in wild-type mice and thus support a similar mechanism in humans.
引用
收藏
页码:552 / 557
页数:6
相关论文
共 32 条
  • [1] QUINIDINE REDUCES BILIARY CLEARANCE OF DIGOXIN IN MAN
    ANGELIN, B
    ARVIDSSON, A
    DAHLQVIST, R
    HEDMAN, A
    SCHENCKGUSTAFSSON, K
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1987, 17 (03) : 262 - 265
  • [2] The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development
    Bailey, CA
    Bryla, P
    Malick, AW
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1996, 22 (1-2) : 85 - 103
  • [3] INTERACTION BETWEEN DIGOXIN AND CALCIUM-ANTAGONISTS AND ANTI-ARRHYTHMIC DRUGS
    BELZ, GG
    DOERING, W
    MUNKES, R
    MATTHEWS, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (04) : 410 - 417
  • [4] Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells
    Cavet, ME
    West, M
    Simmons, NL
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) : 1389 - 1396
  • [5] THE MDR1 GENE-PRODUCT, P-GLYCOPROTEIN, MEDIATES THE TRANSPORT OF THE CARDIAC GLYCOSIDE, DIGOXIN
    DELANNOY, IAM
    SILVERMAN, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 189 (01) : 551 - 557
  • [6] CYCLOSPORINE AND QUINIDINE INHIBITION OF RENAL DIGOXIN EXCRETION - EVIDENCE FOR LUMINAL SECRETION OF DIGOXIN
    DELANNOY, IAM
    KOREN, G
    KLEIN, J
    CHARUK, J
    SILVERMAN, M
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (04): : F613 - F622
  • [7] DOERING W, 1978, MED KLIN, V73, P1085
  • [8] DIGOXIN-QUINIDINE INTERACTION - PHARMACOKINETIC EVALUATION
    HAGER, WD
    FENSTER, P
    MAYERSOHN, M
    PERRIER, D
    GRAVES, P
    MARCUS, FI
    GOLDMAN, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (22) : 1238 - 1241
  • [9] PHARMACOKINETICS OF DIGOXIN AND MAIN METABOLITES DERIVATIVES IN HEALTHY HUMANS
    HINDERLING, PH
    HARTMANN, D
    [J]. THERAPEUTIC DRUG MONITORING, 1991, 13 (05) : 381 - 401
  • [10] HUNTER J, 1993, J BIOL CHEM, V268, P14991